Medtronic, Inc. (MDT) Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe

5/16/2012 10:27:01 AM

PARIS--(BUSINESS WIRE)--As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Medtronic, Inc.

• Medical Devices

• Medical Dev. & Diag. - Product News